European Commission Approves Daiichi Sankyo/AstraZeneca Enhertu Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer

This is a new, concrete European Commission regulatory approval with clear forward implications for the commercial use of Enhertu in first-line HER2-positive metastatic breast cancer. The approval expands the indication for Daiichi Sankyo and AstraZeneca, is supported by DESTINY-Breast09 results showing a 44% reduction in the risk of progression or death versus THP, and triggers an explicitly disclosed $100 million milestone payment from AstraZeneca to Daiichi Sankyo. Importance is high but below a global or unexpected shock because the approval is regional, follows a positive CHMP opinion, and the regimen was already approved in other jurisdictions; surprise is therefore moderate. The approval date is explicit as September 1, 2026, but the exact real-world approval time is not stated, so the timestamp uses the start of that UTC date rather than the 06:30 UTC publication time. The prior decision to create a new regulatory-approval event is retained. Approved stakeholders are limited to the two directly commercializing companies and Roche as the clearly exposed incumbent HER2 regimen provider; indirect CDMOs, diagnostic suppliers, taxane manufacturers, and later-line therapy providers are excluded because the evidence does not establish a sufficiently direct impact.